Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.

Pink Sheet editor and reporters discuss the pending trials of chloroquine for use against coronavirus, expanded access for remdesivir, and the official move of several biologics from regulation as drugs to regulation as biologics. 

Pink Sheet reporter and editor consider the fall-out from the FDA decision to cancel meetings and postpone inspections due to the coronavirus pandemic, as well as look at the new cardiovascular recommendations for Type 2 diabetes drug development.

Manufacturers are on board for ‘Part D Senior Savings Model’ that would set a $35 copay cap, but added risk corridor payments may be the key to getting PBMs to offer the enhanced plans focused on reducing insulin costs for patients.

Pink Sheet reporter and editor consider congressional demands that government-funded coronavirus research produce affordable medicines and vaccines, as well as the one-word change to the biologics transition guidance that may affect the availability of authorized biosimilars.

$195m deferred prosecution agreement with the US DOJ could be followed by civil settlement that's almost as large, illustrating the strong evidence in the generic price-fixing investigation thus far.